Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2025 Jun 30;14(6):3295-3301.
doi: 10.21037/tcr-2024-2589. Epub 2025 Jun 13.

FLAURA2: evidence for escalated first-line therapy in EGFR-mutated non-small cell lung cancer with central nervous system metastases

Fangdi Sun  1 , Joel W Neal  1   2 , Nathaniel J Myall  1
Affiliations
Editorial

FLAURA2: evidence for escalated first-line therapy in EGFR-mutated non-small cell lung cancer with central nervous system metastases

Fangdi Sun et al. Transl Cancer Res. .
No abstract available

Keywords: FLAURA2; Non-small cell lung cancer (NSCLC); central nervous system metastases (CNS metastases); epidermal growth factor receptor (EGFR); osimertinib.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://tcr.amegroups.com/article/view/10.21037/tcr-2024-2589/coif). F.S. has participated in an advisory board for OncoHost and received honoraria from MJH Life Sciences. J.W.N. has received honoraria from CME Matters, Clinical Care Options CME, Research to Practice CME, Medscape CME, Biomedical Learning Institute CME, MLI Peerview CME, Prime Oncology CME, Projects in Knowledge CME, Rockpointe CME, MJH Life Sciences, Medical Educator Consortium, and HMP Education; and consulting fees from AstraZeneca, Genentech/Roche, Exelixis, Takeda Pharmaceuticals, Eli Lilly and Company, Amgen, Iovance Biotherapeutics, Blueprint Pharmaceuticals, Regeneron Pharmaceuticals, Natera, Sanofi/Regeneron, D2G Oncology, Surface Oncology, Turning Point Therapeutics, Mirati Therapeutics, Gilead Sciences, AbbVie, Summit Therapeutics, Novartis, Novocure, Janssen Oncology, Anheart Therapeutics, Bristol-Myers Squibb, Daiichi Sankyo/AstraZeneca, and Nuvation Bio. J.W.N. also receives research funding from Genentech/Roche, Merck, Novartis, Boehringer Ingelheim, Exelixis, Nektar Therapeutics, Takeda Pharmaceuticals, Adaptimmune, GSK, Janssen, AbbVie, Nuvalent, and Novocure. N.J.M. has received research funding from Genentech. The authors have no other conflicts of interest to declare.

Comment on

References

    1. Jänne PA, Planchard D, Kobayashi K, et al. CNS Efficacy of Osimertinib With or Without Chemotherapy in Epidermal Growth Factor Receptor-Mutated Advanced Non-Small-Cell Lung Cancer. J Clin Oncol 2024;42:808-20. 10.1200/JCO.23.02219 - DOI - PMC - PubMed
    1. Rangachari D, Yamaguchi N, VanderLaan PA, et al. Brain metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancers. Lung Cancer 2015;88:108-11. 10.1016/j.lungcan.2015.01.020 - DOI - PMC - PubMed
    1. Ju JS, Huang AC, Tung PH, et al. Brain metastasis, EGFR mutation subtype and generation of EGFR-TKI jointly influence the treatment outcome of patient with EGFR-mutant NSCLC. Sci Rep 2023;13:20323. 10.1038/s41598-023-45815-8 - DOI - PMC - PubMed
    1. Popat S, Ahn MJ, Ekman S, et al. Osimertinib for EGFR-Mutant Non-Small-Cell Lung Cancer Central Nervous System Metastases: Current Evidence and Future Perspectives on Therapeutic Strategies. Target Oncol 2023;18:9-24. 10.1007/s11523-022-00941-7 - DOI - PubMed
    1. Soria JC, Ohe Y, Vansteenkiste J, et al. Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. N Engl J Med 2018;378:113-25. 10.1056/NEJMoa1713137 - DOI - PubMed